The raised guidance and strong Q3 beat signal accelerating momentum in transplant diagnostics and early traction in Specialty Oncology. Watch for Q4 2026 results to confirm the sustainability of Testing Services growth (65% YoY) and whether the Naveris contingent consideration milestones are achieved, which would add further upside.
Price Chart
Executive Summary
CareDx reported Q3 2026 revenue of $139M (up 39% YoY, above the $122M consensus) and GAAP EPS of $0.35 diluted (above the $0.26 consensus). The company raised full-year 2026 revenue guidance to $520M-$530M (from $490M-$500M) and Adjusted EBITDA guidance to $90M-$100M (from $66M-$78M), reflecting strong execution in Testing Services and the addition of Specialty Oncology via the Naveris acquisition closed July 1, 2026.
Key Financial Metrics
Key Facts
- Q3 2026 total revenue of $139M, up 39% YoY from $100M
- Testing Services revenue of $119M, up 65% YoY, including $12M in Specialty Oncology
- Testing Services volume of ~75,900, up 51% YoY
- Patient and Digital Solutions revenue of $20M, up 31% YoY
- GAAP net income of $19M vs $2M in Q3 2025; GAAP diluted EPS $0.35 vs $0.03
- Adjusted EBITDA of $30M vs $15M in Q3 2025; margin 22% vs 15%
- Full-year 2026 revenue guidance raised to $520M-$530M from $490M-$500M
- Full-year 2026 Adjusted EBITDA guidance raised to $90M-$100M from $66M-$78M
- Closed Naveris acquisition on July 1, 2026 for $160M cash plus up to $100M contingent consideration
- Divested Lab Products business on June 30, 2026; Q3 2026 results exclude Lab Products revenue
Financial Impact
Revenue beat consensus by ~$17M (14%); EPS beat consensus by $0.09 (35%); guidance raised by $30M at midpoint for revenue and $23M at midpoint for Adjusted EBITDA
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Testing Services | $119.2M | +65.0% |
| Patient and Digital Solutions | $20.2M | +31.0% |
Risk Factors
- Testing Services revenue includes $15M in prior period revenue, which may not recur
- Naveris contingent consideration of up to $100M could pressure future cash flows if milestones are met
- Integration of Naveris and scaling of Specialty Oncology pipeline (AlloHeme, HistoMap Kidney) carry execution risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001217234-26-000059 |
| Document: cdna-20261029.htm | 0001217234-26-000059 |
| Document: 0001217234-26-000059-index-headers.html | 0001217234-26-000059 |
| Document: 0001217234-26-000059-index.html | 0001217234-26-000059 |
| Document: 0001217234-26-000059.txt | 0001217234-26-000059 |
| 8-K Data (Synthetic) | 0001217234-26-000059 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 29, 2026 3d ago | 8-K | $79.09 | awaiting T+60 | awaiting T+60 | $87.41 (+10.53%) |
Oct 29, 2026 3d ago | Institutional Cluster | $71.52 | awaiting T+60 | awaiting T+60 | $87.41 (−22.22%) |
Aug 6, 2026 12w ago | Insider Cluster | $46.69 | awaiting T+60 | awaiting T+60 | $87.41 (+87.21%) |
Aug 4, 2026 12w ago | 144 | $45.50 | awaiting T+60 | awaiting T+60 | $87.41 (+92.11%) |
Jul 17, 2026 15w ago | Insider Cluster | $39.73 | awaiting T+60 | awaiting T+60 | $87.41 (+120.01%) |
Jun 16, 2026 19w ago | Insider Cluster | $23.48 | awaiting T+60 | awaiting T+60 | $87.41 (+272.27%) |
Jun 5, 2026 21w ago | DEFA14A | $21.95 | awaiting T+60 | awaiting T+60 | $87.41 (+298.22%) |
Apr 28, 2026 26w ago | S-3ASR | $20.80 $37.14 | ▲ +78.56% | ▲ +74.45% | $87.41 (+320.24%) |
Apr 16, 2026 28w ago | 8-K | $22.42 $28.76 | ▲ +28.28% | ▲ +21.23% | $87.41 (+289.88%) |
Feb 25, 2026 35w ago | 8-K/A | $18.82 $21.63 | ▲ +14.93% | ▲ +6.76% | $87.41 (+364.45%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers